Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA5163||ECOG-ACRIN||INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis||Adult CIRB - Late Phase Emphasis||Available to Open|
|MAY2015-05-01||CLO-Mayo Clinic||Randomized, double-blind, placebo-controlled trial of Meriva® (curcuminoids) as a candidate chemoprevention agent for gastric carcinogenesis||Cancer Prevention and Control CIRB||Available to Open|
|NRG-DT001||NRG||A Phase 1B Trial of Neoadjuvant AMG 232 Concurrent with Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)||Adult CIRB - Early Phase Emphasis||Available to Open|
|AALL1231||COG||A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy): A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AALL1732||COG||A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy||Pediatric CIRB||Available to Open|
|S1803||SWOG||Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)||Adult CIRB - Late Phase Emphasis||Available to Open|
|9706||ETCTN||Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial)||Adult CIRB - Early Phase Emphasis||Available to Open|
|ARET12P1||COG||A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma||Pediatric CIRB||Available to Open|
|ABTC-1701||ABTC||Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients||Adult CIRB - Early Phase Emphasis||Available to Open|
|10212||ETCTN||A Phase 1b/2 study of Pinometostat in Combination with standard induction chemotherapy in newly diagnosed Acute Myeloid Leukemia with MLL rearrangement||Adult CIRB - Early Phase Emphasis||Available to Open|